title: First integrin inhibitor since Tysabri nears approval for IBD.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016023:Integrins / Q000037:antagonists & inhibitors*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D000069442:Natalizumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016023:Integrins; D000069442:Natalizumab; C543529:vedolizumab
references.citation: N Engl J Med. 2013 Aug 22;369(8):699-710
references.pmid: 23964932
references.citation: J Pharmacol Exp Ther. 2012 Sep;342(3):861
references.pmid: 22893217
references.citation: J Immunol. 2013 Mar 1;190(5):1961-73
references.pmid: 23365083
references.citation: Nat Biotechnol. 2005 Apr;23(4):397-8
references.pmid: 15815649
references.citation: J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
references.pmid: 19509315